Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
Authors
Keywords
-
Journal
Expert Review of Neurotherapeutics
Volume 16, Issue 10, Pages 1131-1139
Publisher
Informa UK Limited
Online
2016-08-23
DOI
10.1080/14737175.2016.1227242
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
- (2016) Venkat Reddy et al. DRUG DISCOVERY TODAY
- Features of Human CD3+CD20+T Cells
- (2016) Elisabeth Schuh et al. JOURNAL OF IMMUNOLOGY
- Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis
- (2015) Manjari Lahiri et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis
- (2015) Dominic Borie et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
- (2015) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- CD19 as a molecular target in CNS autoimmunity
- (2014) Olaf Stüve et al. ACTA NEUROPATHOLOGICA
- The efficacy of novel B cell biologics as the future of SLE treatment: A review
- (2014) Ameer Kamal et al. AUTOIMMUNITY REVIEWS
- Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
- (2014) Arumugam Palanichamy et al. JOURNAL OF IMMUNOLOGY
- Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial
- (2014) Ludwig Kappos et al. LANCET NEUROLOGY
- Trial and error in clinical studies: lessons from ATAMS
- (2014) Fred Lühder et al. LANCET NEUROLOGY
- The Charcot Lecture | Beating MS: A story of B cells, with twists and turns
- (2014) Stephen L Hauser Multiple Sclerosis Journal
- Alemtuzumab: The advantages and challenges of a novel therapy in MS
- (2014) T. Menge et al. NEUROLOGY
- Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
- (2014) Paul Emery et al. PLoS One
- CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination
- (2014) Janet E. Holley et al. Multiple Sclerosis and Related Disorders
- Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study
- (2013) Eduardo F. Mysler et al. ARTHRITIS AND RHEUMATISM
- B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design
- (2013) Venkat Reddy et al. ARTHRITIS RESEARCH & THERAPY
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
- (2012) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination
- (2012) Robert A. Eisenberg et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
- (2010) F. Morschhauser et al. ANNALS OF ONCOLOGY
- Helminth-induced CD19+CD23hi B cells modulate experimental allergic and autoimmune inflammation
- (2010) Mark S. Wilson et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Cutting Edge: Novel Function of B Cell-Activating Factor in the Induction of IL-10-Producing Regulatory B Cells
- (2010) M. Yang et al. JOURNAL OF IMMUNOLOGY
- Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial
- (2009) Clifton O. Bingham et al. ARTHRITIS AND RHEUMATISM
- New approaches of B-cell-directed therapy: beyond rituximab
- (2009) Thomas Dörner et al. CURRENT OPINION IN RHEUMATOLOGY
- Helminth Antigens Modulate Immune Responses in Cells from Multiple Sclerosis Patients through TLR2-Dependent Mechanisms
- (2009) J. Correale et al. JOURNAL OF IMMUNOLOGY
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
- (2009) Eva Havrdova et al. LANCET NEUROLOGY
- A granulocyte-macrophage colony–stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties
- (2009) Moutih Rafei et al. NATURE MEDICINE
- Helminth infections associated with multiple sclerosis induce regulatory B cells
- (2008) Jorge Correale et al. ANNALS OF NEUROLOGY
- Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started